High-risk HPV genotyping in the follow-up of women treated conservatively for microinvasive cervical cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 154-157

  Cairns, Mary ^a   Cuschieri, Kate S ^b   Cubie, Heather A ^b   Cruickshank, Margaret E ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Human papillomavirus (HPV); Microinvasive cervical cancer

Indexed keywords

PARAFFIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; INVASIVE CARCINOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TUMOR BIOPSY; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GYNECOLOGIC SURGICAL PROCEDURES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INFERTILITY, FEMALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 74249115084     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c3a6b6     Document Type: Article

References (10)

1. Munoz N, Bosch X, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
2. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57:68-72.
3. Sigurdsson K, Taddeo F, Benediktsdottir K, et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer. 2007;121:2682-2687.
4. Cancer of Cervix Uteri and Carcinoma in situ of Cervix Uteri: Trends in Incidence 1980-2004. Scottish Cancer Registry, ISD. www.isdscotland.org/isd/ files/cancer-cervix-insitu-inc.xls and www.isdscotland.org/isd/files/cancer- cervix-inc.xls.
5. Sigurdsson K. The Icelandic and Nordic Cervical Screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand. 1999;78:478-485.
6. Cairns M, Cruickshank ME. A review of women with microinvasive cervical cancer in the Grampian region. J Low Genit Tract Dis. 2007;11:290-293.
7. Verguts J, Bronselaer B, Donders G, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG. 2006;113:1303-1307.
8. Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99:S7-S11.
9. Bendet JL, Bender H, Jones H 3rd, et al. FIGO staging classification and clinical practice guidelines of gynaecological cancer. Int J Gynaecol Obstet. 2000;70:209-262.
10. Introduction of HPV Vaccine into the National Immunisation Programme. May 2008. www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/ Professionalletters/Chiefmedicalofficerletters/DH-08452.